To establish the clinical relevance of our findings, we rationalized that IFNGR1Low SKCMs with impaired IFN-γ signaling and patient melanomas resistant to ICBs would house activated mTOR and JAK1/2 to some extent. The gene discussed is JAK1; the disease is melanoma.